Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • NovoThirteen

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

    Growth driven by increased sales in diabetes and obesity markets

    - PMLiVE

    Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

    The transition will help the company meet the rising global demand in the obesity market

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    - PMLiVE

    Novo Nordisk appoints Maziar Mike Doustdar as president and CEO

    Doustdar has most recently been serving as Novo’s executive vice president of international operations

    - PMLiVE

    Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

    The companies will launch four development programmes for potential small molecule therapies

    - PMLiVE

    Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

    Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

    - PMLiVE

    Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

    UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

    - PMLiVE

    Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

    The company is expecting to file for the first regulatory approval of the drug next year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links